385 Employees Resign from FDA’s CDER Division in First Half of 2025 Amid HHS Overhaul

The Center for Drug Evaluation and Research (CDER), a division of the U.S. Food and Drug Administration (FDA), has experienced a significant increase in employee resignations during the first half of 2025. According to recent data, 385 employees left their positions at CDER between January and June this year, marking a sharp rise compared to fewer than 130 departures during the same period in 2024. This development coincides with an ongoing overhaul within the Department of Health and Human Services (HHS).

The surge in resignations comes amid broader structural changes at HHS, though specific reasons for the exodus have not been disclosed. The reported figures highlight a notable shift in staffing trends within one of the FDA’s key divisions responsible for evaluating and approving drugs for public use. The data underscores potential challenges facing CDER as it navigates these transitions while maintaining its regulatory responsibilities. Further details on the implications of these departures remain under analysis.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 17, 2025

Author

Mark Chiang